RICH PHARMACEUTICALS, INC. (OTCMKTS:RCHA) Files An 8-K Changes in Registrant’s Certifying AccountantItem 9.01
| (a) | Dismissal of Anton & Chia, LLP (“Anton & Chia”) |
On October 29, 2017 (the “Dismissal Date”), the Board of Directors of the Company determined to dismiss Anton Chia as its independent registered public accounting firm.
Anton Chia has not prepared any reports on the audited financial statements of the Company.
During the period commencing with the engagement of Anton Chia on September 5, 2017 and through the Dismissal Date, there were no disagreements (as defined in Item 304 of Regulation S-K) with Anton Chia on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Anton Chia, would have caused it to make reference in connection with its opinion to the subject matter of the disagreement. Further, during the period commencing with the engagement of Anton Chia on September 5, 2017 and through the Dismissal Date, there were no reportable events (as defined in Item 304(a)(1)(v) of Regulation S-K).
The Company provided Anton Chia with a copy of this Report prior to its filing with the Securities and Exchange Commission (the “SEC”) and requested Anton Chia to furnish the Company with a letter addressed to the SEC, stating whether or not it agrees with the statements made above and, if not, stating the respects in which they do not agree. A copy of such letter will be filed by amendment once it is received.
| (b) | Engagement of Fruci&AssociatesII,PLLC (“Fruci”) |
On October 31, 2017 (the “Engagement Date”), the Company’s Board of Directors approved the appointment of Fruci as the Company’s independent registered public accounting firm. During the Company’s two most recent fiscal years, the subsequent interim periods thereto, and through the Engagement Date, neither the Company nor anyone on its behalf consulted Fruci regarding either (1) the application of accounting principles to a specified transaction regarding the Company, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements; or (2) any matter regarding the Company that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions to Item 304 of Regulation S-K) or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).
| Item 9.01. | Financial Statements and Exhibits. |
(d)Exhibits
The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.
|
Exhibit No. |
Description |
|
Letter regarding change in certifying accountant (to be filed by amendment) |
About RICH PHARMACEUTICALS, INC. (OTCMKTS:RCHA)
Rich Pharmaceuticals, Inc. is a development-stage company. The Company is a biopharmaceutical company focused on developing and commercializing therapies in oncology. The Company is developing 12-O-tetradecanoylphorbol-13-acetate (RP-323) for the treatment of Hodgkin’s lymphoma (HL), Acute Myelogenous Leukemia (AML) and to cause elevation of white blood cells in patients depleted of these elements due to various conditions. RP-323 is a naturally occurring compound. RP-323 converts cancer cells to normal cells, a process called differentiation. It is also observed in some instances to cause cancer cell death. Clinical studies in over 100 cancer patients demonstrated the ability of RP-323 to stimulate the production of white blood cells and neutrophils. The Company has no products ready for commercialization. The Company had no revenues during the period ending March 31, 2016.
